Fusobacterial liver abscess: a case report and review of the literature

Dilip Jayasimhan 1*, Linus Wu 2 and Paul Huggan 1*

Abstract

Background: Fusobacteria are facultative anaerobic gram-negative bacilli which cause a range of invasive infections, amongst which pyogenic liver abscesses are rare. We describe a case of Fusobacterium nucleatum liver abscess and review the relevant literature.

Case presentation: A 51-year-old lady presented with a 4-day history of abdominal pain, diarrhoea, fever, rigors, and lethargy. Imaging revealed an abscess which was drained. Cultures of the blood and abscess aspirate grew Fusobacterium nucleatum and Prevotella pleuritidis respectively. She achieved full recovery following treatment. A MEDLINE search was undertaken using free-text and Medical Subject Headings (MeSH), keywords “Fusobacterium” and “Liver abscess”. Non-English language reports and cases without confirmed growth of Fusobacterium species were excluded. Additional cases were identified by surveying the references of each report and by using the same keywords in a web-based search. Forty-eight cases were identified, 41 in men. The median age was 42.5, with an interquartile range of 33. F. nucleatum and F. necrophorum were involved in 22 cases each, and 4 cases were not further speciated. Among cases of F. nucleatum liver abscess, nine were attributed to periodontal disease, four to lower gastrointestinal tract disease, one to Lemierre’s Syndrome, and eight were considered cryptogenic. All patients treated made a full recovery. Antimicrobial treatment duration ranged from 2 weeks to 6 months with a median of 6 weeks.

Conclusion: Fusobacterium nucleatum is an uncommon cause of liver abscess generally associated with good clinical outcomes with contemporary medical and surgical care.

Keywords: Fusobacterium, Liver abscess, Review, Case reports, Lemierre’s syndrome, Periodontal diseases

Background

Fusobacteria are arguably unique amongst non-spore forming anaerobes in their ability to cause severe, clinically distinct, mono-microbial infections in a range of organs, often with severe sequelae as originally described by Lemierre and others in the first half of the twentieth century [1]. Fusobacterial infections can affect the head and neck, the lung and pleura, the gastro-intestinal organs, and the female genital tract [2]. Despite their ability to cause severe infections, fusobacterium species are uncommonly identified as pathogens in clinical practice, accounting for less than 1% of anaerobic bacteremias. Regional population-based studies have described the incidence of Fusobacterial bacteraemia to be around 0.55 per 100,000 people per year [3, 4], and that of clinically significant infections to be 0.99 per 100,000 people per year [2]. Whilst the clinical presentations associated with fusobacterial infections are well defined, little is known about the clinical progress and outcomes of specific syndromes [1, 5, 6]. Fusobacteria are a particularly uncommon cause of pyogenic liver abscesses. Therefore, our objective is to describe a case of this condition and to summarise the presentation and outcomes of Fusobacterial liver abscesses through a review of the relevant literature.

Case presentation

A 51-year-old previously fit and well woman who recently returned from Samoa presented with a four-day history of watery non-bloody diarrhoea, associated with...
generalised abdominal pain, fevers, chills, and lethargy. Family members reported similar symptoms of milder severity. On admission, she was febrile with a temperature of 38 °C, with otherwise unremarkable vital signs. Examination of the abdomen found a palpable mass in the right upper quadrant. There were no signs of periodontal disease on inspection of the oral cavity. Laboratory tests showed a white cell count of 26.7 × 10^9/L, deranged liver enzymes (alanine transaminase 263 U/L, aspartate transaminase 177 U/L, bilirubin 15 mg/L), and a C-reactive protein of 407 mg/L. A Computed Tomography (CT) scan of the abdomen with contrast revealed a 90 × 92 × 93 mm mixed density lesion in segment II and III of the liver. The lesion was percutaneously drained under ultrasound guidance. Cultures of the aspirated abscess fluid and blood both grew anaerobic gram-negative bacilli. Following abscess drainage and treatment with ceftriaxone and metronidazole, the patient continued to experience fevers and diarrhea and her inflammatory markers did not improve. A follow-up ultrasound scan of the liver revealed an emerging focal abscess in segment IV-b of the liver. The initial CT scan was then retrospectively reviewed to reveal subtle heterogeneous changes in this segment; however, no demarcated fluid collection was present at the time. The two abscesses were not contiguous with but in close proximity to each other. This abscess was also percutaneously drained. Samples from the blood culture were further identified as *Fusobacterium nucleatum* via Biomerieux Vitek (Knowledge database version 2.0) MALDI-TOF (Matrix assisted Laser Desorption/Ionisation - Time of Flight) mass spectrometry with a confidence of 99.9%. Cultures of the initial aspirate were not identifiable using MALDI-TOF and were referred to a quaternary level laboratory in Auckland and later identified as *Prevotella pleuritidis* through 16 s ribosomal Ribonucleic Acid identification. Both specimens underwent susceptibility testing using Clinical Laboratory Standards Institute (CLSI) – recommended media and breakpoint determination using MIC gradient strips. The *Prevotella pleuritidis* was tested on Brucella agar with sheep blood, haemin, and vitamin K, while the *F. nucleatum* required Brain Heart Infusion agar to achieve satisfactory growth.

Given the growth of a second organism common to the periodontal flora and in the absence of symptoms, signs, or imaging evidence of bowel pathology, a periodontal, rather than a gastrointestinal, source was considered more likely and no further evaluation of the large bowel was undertaken.

Treatment was changed on day nine to a two-week course of IV ertapenem, prior to susceptibilities being known, followed by four further weeks of oral amoxicillin-clavulanate. The patient recovered fully.

Although *Fusobacterium* was only grown in the blood culture and not in the aspirate culture, we were confident in treating this case as a *Fusobacterial pyogenic* liver abscess. The aspirate sample was collected afterhours and was not processed until 7 hours later. This delay could have significantly affected our ability to identify this anaerobic organism using standard culture methods, especially in the setting of antimicrobial therapy.

**Review of literature**

We conducted a literature review of cases of liver abscess associated with *Fusobacterium* species.

**Methods**

A MEDLINE Medical Subject Headings (MeSH®) and a free text search were used using the keywords “Fusobacterium” AND “liver abscess”. The search was further limited to case reports in the English language and on human subjects. Cases in which a liver abscess was demonstrated by appropriate imaging techniques or direct visualization, and was associated with a positive culture (blood, abscess fluid, or tissue) for a Fusobacterium species were included. Additional studies were included through reviewing the references of the selected case reports. One additional case was identified when the same keywords were entered into a web-based search engine (Google TM, San Francisco, CA).

**Results**

Forty-eight cases were identified using the above search strategy. Table 1 summarises them. Forty-one cases involved males, and seven involved females. The age of the patients ranged from 17 to 78 years with a median of 42.5 years and an interquartile range of 33 years. Twenty-two cases identified *F. nucleatum* and 22 cases identified *F. necrophorum* as the aetiological pathogen. In another five cases, the microbe was not identified past *Fusobacterium spp.* 29 of 48 cases involved multiple abscesses as opposed to a single abscess. The most common presumed sources were the periodontal flora (12 cases) and Lemierre's Syndrome (10 cases), followed by the lower GI tract (six cases), the upper GI tract (four cases), and the cervix (one case). Fifteen cases were considered cryptogenic.

Among the cases that identified *F. nucleatum*, the most common presumed source was the periodontal flora (nine out of 22 cases). Eight cases were cryptogenic. The presumed source was considered to be the lower GI tract in four cases, and Lemierre's syndrome in one case.

Treatment mostly consisted of abscess drainage and prolonged antimicrobial therapy. The duration of
| Case Report | Age | Sex | Organism (specimen cultured) | Treatment | Multiple or Single | Presumed Source |
|-------------|-----|-----|------------------------------|-----------|--------------------|-----------------|
| 1 [35]      | 35  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of the two largest abscesses (R). | Multiple | Oropharynx (PF) |
|             |     |     |                              | - Piperacillin/tazobactam (UTP) |         |                 |
|             |     |     |                              | - Ertapenem (8 weeks) |         |                 |
| 2 [36]      | 48  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of abscess (R) | Multiple | Oropharynx (PF) |
|             |     |     |                              | - Ceftriaxone and metronidazole (3 days) |         |                 |
|             |     |     |                              | - IV penicillin and metronidazole (10 weeks) |         |                 |
| 3 [37]      | 23  | M   | *F. nucleatum* (blood culture and abscess aspirate) | - Drainage of abscess (R) | Multiple | Unidentified |
|             |     |     |                              | - Piperacillin/tazobactam (UTP) |         |                 |
|             |     |     |                              | - Ertapenem (6 weeks) |         |                 |
| 4 [38]      | 58  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of pelvic abscess (S) | Multiple | Lower GI tract (diverticulitis) |
|             |     |     |                              | - Defunctioning colostomy |         |                 |
|             |     |     |                              | - Ertapenem (6 weeks) |         |                 |
|             |     |     |                              | - Low molecular weight heparin (2 weeks) |         |                 |
| 5 [39]      | 48  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of two largest abscesses (R) | Multiple | Unidentified |
|             |     |     |                              | - Piperacillin/tazobactam (14 days) |         |                 |
|             |     |     |                              | - Moxifloxacin + oral penicillin (14 days) |         |                 |
| 6 [40]      | 49  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of largest hepatic abscess(R) | Multiple | Oropharynx (PF) |
|             |     |     |                              | - Laparoscopic cholecystectomy |         |                 |
|             |     |     |                              | - Laparoscopic appendicectomy |         |                 |
|             |     |     |                              | - IV ertapenem (UTP) |         |                 |
| 7 [41]      | 59  | F   | *F. nucleatum*, *Treponema denticola*, *Prevotella intermedia*, *Porphyromonas gingivalis*, *Bacteroides vulgatus* (tissue culture and abscess aspirate culture) | - None | Multiple | Oropharynx (PF) |
| 8 [28]      | 59  | M   | *F. nucleatum* (blood culture) | - Imipenem/cilastatin 500 mg BD (4 days) | Single | Oropharynx (PF) |
|             |     |     |                              | - Oral clindamycin 600 mg BD (UTP) |         |                 |
| 9 [42]      | 58  | M   | *F. nucleatum* (abscess drainage) | - Drainage of hepatic abscess (R) | Single | Oropharynx (PF) |
|             |     |     |                              | - Oral ciprofloxacin, vancomycin, and gentamicin (UTP) |         |                 |
|             |     |     |                              | - IV metronidazole (12 days) |         |                 |
|             |     |     |                              | - Oral metronidazole (3 weeks) |         |                 |
| 10 [43]     | 24  | M   | *F. nucleatum* (blood culture) | - IV metronidazole (4 weeks) | Single | Oropharynx (PLS) |
|             |     |     |                              | - Oral metronidazole (2 weeks) |         |                 |
| 11 [44]     | 62  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of abscess(NOS) | Single | Lower GI tract (biopsies) |
|             |     |     |                              | - IV antibiotics (agent and time period not specified) |         |                 |
| 12 [45]     | 78  | F   | *F. nucleatum* (abscess aspirate) | - Drainage of hepatic abscess(R) | Single | Lower GI tract (diverticular disease) |
|             |     |     |                              | - Drainage of subphrenic collection |         |                 |
|             |     |     |                              | - Metronidazole (6 weeks) |         |                 |
| 13 [46]     | 68  | M   | *F. nucleatum* (blood cultures) | - IV cefotaxime 1 g Q8H and IV metronidazole 500 mg Q8H (24 days) | Single | Unidentified |
|             |     |     |                              | - Oral metronidazole (2 weeks) |         |                 |
|             |     |     |                              | - Enoxaparin 20 mg daily (UTP) |         |                 |
| 14 [47]     | 54  | F   | *F. nucleatum* (abscess aspirate) *S. viridans* (abscess aspirate) *Actinomyces odontolyticus* (abscess aspirate) | - Drainage of hepatic abscess (R) | Multiple | Oropharynx (PF) |
|             |     |     |                              | - Extraction of 11 teeth |         |                 |
|             |     |     |                              | - IV antibiotics (agent and period of treatment unspecified) |         |                 |
| 15 [47]     | 69  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of hepatic abscesses (R) | Multiple | Oropharynx (PF) |
|             |     |     |                              | - IV antibiotics (unspecified agent or time period) |         |                 |
|             |     |     |                              | - Dental surgery |         |                 |
| 16 [48]     | 40  | M   | *F. nucleatum* (blood culture) | - IV cefuroxime, metronidazole, and erythromycin (14 days) | Multiple | Unidentified |
|             |     |     |                              | - Oral metronidazole (5 weeks) |         |                 |
| 17 [49]     | 29  | M   | *F. nucleatum* (abscess aspirate) | - Drainage of the largest abscess (R) | Multiple | Oropharynx (PF) |
|             |     |     |                              | - Metronidazole (10 days, route unspecified) |         |                 |
|             |     |     |                              | - Open drainage other abscesses (S) |         |                 |
|             |     |     |                              | - Oral metronidazole (4 weeks) |         |                 |
| Case ID | Year | Age | Gender | Organism (isolated from) | Isolation Method | Initial Treatment | Follow-up Treatment | Clinical Site | Case Description |
|---------|------|-----|--------|--------------------------|----------------|-------------------|-------------------|--------------|------------------|
| 18 [50] | 24   | M   | 18     | Actinomyces israeli (abscess aspirate) | F. nucleatum (Abscess aspirate) | - Open drainage of abscess (S) | - Penicillin G 20 million units (4 weeks) | Single | Unidentified |
| 19 [51] | 70   | M   | 19     | F. nucleatum (abscess aspirate) | - Metronidazole (2 weeks, route unspecified) | - Oral metronidazole (2 weeks) | Multiple | Unidentified |
| 20 [52] | 47   | M   | 20     | F. nucleatum (tissue culture) Peptostreptococcus (tissue culture) | - Open resection of all three lesions, (S) | - IV penicillin (3 weeks) | - Repeat laparotomy 49 days later | Multiple | Unidentified |
| 21 [53] | 44   | F   | 21     | F. nucleatum (blood culture) | - Drainage of abscess (R) | - Ceftriaxone and oral metronidazole (13 days) | Single | Unidentified |
| 22 [54] | 60   | M   | 22     | F. nucleatum (abscess aspirate) | - Piperacillin/tazobactam (3 days) | - Etapenem (1 day) | Multiple | Lower GI tract (diverticulitis) |
| 23 [55] | 28   | M   | 23     | F. necrophorum (blood culture) | - Ceftriaxone (6 days) | - Meropenem (14 days) | Single | Oropharynx (PLS) |
| 24 [56] | 30   | M   | 24     | F. necrophorum (blood culture) | - Piperacillin/tazobactam and metronidazole (UTP) | - Oral levofloxacin and metronidazole (UTP) | Multiple | Unidentified |
| 25 [57] | 48   | M   | 25     | F. necrophorum (blood culture) | - Cefotiam (UTP) | - Doripenem (19 days) | Multiple | Oropharynx (PLS) |
| 26 [20] | 40   | M   | 26     | F. necrophorum (tissue culture) | - Drainage of abscess (R) | - Sulbactam/cefoperazone (10 days) | Single | Unidentified |
| 27 [58] | 25   | M   | 27     | F. necrophorum (blood culture) | - Piperacillin/tazobactam (UTP) | - IV penicillin (6 weeks) | Single | Oropharynx (PLS) |
| 28 [59] | 34   | M   | 28     | F. necrophorum (left subphrenic collection) | - Vancomycin and meropenem (UTP) | - Tigecyclin and meropenem (UTP) | Multiple | Upper GI tract (HPB) |
| 29 [60] | 44   | F   | 29     | F. necrophorum (blood culture) | - IV ampicillin/sulbactam and ciprofloxacin (5 days) | - Oral amoxicillin/clavulanate (1 month) | Single | Cervix |
| 30 [61] | 18   | M   | 30     | F. necrophorum (blood culture) | - Aspiration of abscess (R) | - Piperacillin/tazobactam and clindamycin (5 weeks) | Single | Oropharynx (PLS) |
| 31 [62] | 21   | M   | 31     | F. necrophorum (abscess drainage) F. nucleatum (peritonsillar abscess) | - Drainage of the largest hepatic abscess (R) | - Piperacillin/tazobactam and metronidazole (6 weeks) | Multiple | Oropharynx (PLS) |
| 32 [10] | 25   | M   | 32     | F. necrophorum (abscess aspirate) Prevotella spp. (blood culture and abscess aspirate) | - Drainage of abscess | - Removal of diseased teeth | Single | Oropharynx (PF) |
| 33 [11] | 64   | M   | 33     | F. necrophorum (abscess aspirate) | - Aspiration of abscess (R) | - Oral metronidazole and oral ciprofloxacin (UTP) | Multiple | Lower GI tract (haemorrhoids) |
| 34 [63] | 22   | M   | 34     | F. necrophorum (abscess aspirate) | - Aspiration of abscess (R) | - Gentamicin, clarithromycin, metronidazole, ceftriaxone and low molecular weight heparin (6 weeks) | Multiple | Oropharynx (PLS) |
treatment was specified in 39 cases. Among them, the minimum duration was 2 weeks, and the maximum was 6 months, with a median of 6 weeks, and an interquartile range of 2 weeks. The duration was less than 4 weeks in five cases, between four to 8 weeks in 26 cases, and more than 8 weeks in eight case. Commonly used antibiotics include beta-lactams (in combination with metronidazole in some cases), carbapenems, metronidazole monotherapy, and less frequently fluoroquinolones.

Treatment outcomes were favourable with 47 of 48 cases reporting complete recovery.
Discussion

Whilst the essential features of disease caused by Fusobacteria have been recognised for over a century, presentations remain uncommon and widely distributed across medical specialties [1]. Thus the historical background, aetiology, and likely clinical outcomes of fusobacterial disease are poorly understood by most clinicians. This report demonstrates the common features of fusobacterial liver abscess and by combining individual reports and case series provides insights into the associated spectrum of underlying illness.

Loefler identified a thin, gram-negative rod present in necrotic tissue in calf diptheriae in 1884 [7]. The term ‘necrobacillosis’ was coined by Bang, who isolated the organism from diseased cattle and pigs [8]. Koch’s postulates were satisfied accidentally when Schmorl and an assistant suffered pyogenic infection of their fingers whilst working with diseased rabbits, samples from both of which yielded Fusobacteria [5]. Cases of de novo necrobacillosis were described in humans by the turn of the twentieth century. Lemierre gave his classic dissertation on anaerobic bacteremia in 1936, earning the right to an eponymous syndrome of tonsillar abscess progressing to internal jugular vein thrombosis, distant abscess formation, and overwhelming sepsis [9].

In the twentieth century it was axiomatic, based on very little evidence, that Fusobacteria were part of the normal human oropharyngeal, gastro-intestinal (GI) tract and female genital tract flora. The apparent rarity of illness caused by these organisms reinforced the notion that they were opportunists, causing illness only when natural barriers to infection were compromised [1, 10, 11]. Contemporary studies have shed light on the true environmental niche and pathogenic potential of Fusobacteria in general and Fusobacterium nucleatum specifically. Fusobacterium nucleatum is a major constituent of the gingival, oropharyngeal and together with F. necrophorum, the appendiceal flora. Neither organism is a component of the healthy normal human oropharyngeal, gastro-intestinal tract flora. The essential features of disease caused by Fusobacterium nucleatum, F. necrophorum and F. nucleatum, were not understood when Schmorl and an assistant suffered pyogenic infection of their fingers whilst working with diseased rabbits, samples from both of which yielded Fusobacteria [5]. Cases of de novo necrobacillosis were described in humans by the turn of the twentieth century. Lemierre gave his classic dissertation on anaerobic bacteremia in 1936, earning the right to an eponymous syndrome of tonsillar abscess progressing to internal jugular vein thrombosis, distant abscess formation, and overwhelming sepsis [9].

In the twentieth century it was axiomatic, based on very little evidence, that Fusobacteria were part of the normal human oropharyngeal, gastro-intestinal (GI) tract and female genital tract flora. The apparent rarity of illness caused by these organisms reinforced the notion that they were opportunists, causing illness only when natural barriers to infection were compromised [1, 10, 11]. Contemporary studies have shed light on the true environmental niche and pathogenic potential of Fusobacteria in general and Fusobacterium nucleatum specifically. Fusobacterium nucleatum is a major constituent of the gingival, oropharyngeal and together with F. necrophorum, the appendiceal flora. Neither organism is a component of the healthy normal human oropharyngeal, gastro-intestinal tract flora. The essential features of disease caused by Fusobacterium nucleatum, F. necrophorum and F. nucleatum, were not understood when Schmorl and an assistant suffered pyogenic infection of their fingers whilst working with diseased rabbits, samples from both of which yielded Fusobacteria [5]. Cases of de novo necrobacillosis were described in humans by the turn of the twentieth century. Lemierre gave his classic dissertation on anaerobic bacteremia in 1936, earning the right to an eponymous syndrome of tonsillar abscess progressing to internal jugular vein thrombosis, distant abscess formation, and overwhelming sepsis [9].

In the twentieth century it was axiomatic, based on very little evidence, that Fusobacteria were part of the normal human oropharyngeal, gastro-intestinal (GI) tract and female genital tract flora. The apparent rarity of illness caused by these organisms reinforced the notion that they were opportunists, causing illness only when natural barriers to infection were compromised [1, 10, 11]. Contemporary studies have shed light on the true environmental niche and pathogenic potential of Fusobacteria in general and Fusobacterium nucleatum specifically. Fusobacterium nucleatum is a major constituent of the gingival, oropharyngeal and together with F. necrophorum, the appendiceal flora. Neither organism is a component of the healthy normal human oropharyngeal, gastro-intestinal tract flora. The essential features of disease caused by Fusobacterium nucleatum, F. necrophorum and F. nucleatum, were not understood when Schmorl and an assistant suffered pyogenic infection of their fingers whilst working with diseased rabbits, samples from both of which yielded Fusobacteria [5]. Cases of de novo necrobacillosis were described in humans by the turn of the twentieth century. Lemierre gave his classic dissertation on anaerobic bacteremia in 1936, earning the right to an eponymous syndrome of tonsillar abscess progressing to internal jugular vein thrombosis, distant abscess formation, and overwhelming sepsis [9].

Indeed, our review of fusobacterial pyogenic liver abscesses showed a low prevalence of general risk factors for liver abscess including malignancy, dialysis treatment, and older age [4]. Most cases occurred in young or middle-aged, immunocompetent individuals with risk factors for haematogenous spread of Fusobacteria such as periodontal disease and recent pharyngitis.

Attribution of the lower GI tract as a source of liver abscess was relatively uncommon and the grounds for doing so were often unclear. The utility of investigating for a presumed source is unknown at this point due to the lack of research assessing this particular question. Our findings support the contention that the majority of disseminated fusobacterial infections originate from the oral cavity even without symptoms of a dental disease. Dental X-Rays to identify possible dental abscesses and cavities or more sophisticated imaging modalities of the oral cavity and the sinuses may be of the most benefit, should clinicians choose to investigate the underlying sources of bacteremia in patients without localising symptoms [16].

Among cases where F. necrophorum were cultured, only three of the 23 liver abscesses were associated with a co-pathogen. None of these cases had clinical findings consistent with classic Lemierre syndrome. Whilst the environmental niche of F. necrophorum is less understood than that of F. nucleatum, it is among the most commonly identified cause of tonsillar abscess after Lancefield Group A beta-hemolytic streptococci [17, 18]. This potentially points to a more evolved role for F. necrophorum as a human pathogen.

We observed good outcomes with appropriate source control and antimicrobial therapy. The only case involving a fatalia was a post-mortem diagnosis and treatment had not been initiated. There was significant variation between studies with regards to the choice and duration of antimicrobial therapy. Current evidence suggests the need for prolonged antimicrobial therapy for patients with liver abscess and risk factors for treatment failure. These include malignancy, older age, presence of septic shock at presentation, certain biochemical derangements (e.g. anaemia, azotaemia, and hyperbilirubinaemia), and an Acute Physiology and Chronic Health Evaluation (APACHE) II score of more than 15 [19–21].

Routine prolonged broad-spectrum antimicrobial therapy may not be warranted in cases of fusobacterial liver abscess with a presumed oral or periodontal origin, especially in the setting of abscess drainage. Fusobacteria remain highly susceptible to beta-lactams. Studies on susceptibility patterns have shown no increase in amoxicillin-resistant Fusobacteria over the past decade [22–24]. They are unlikely to be accompanied by highly resistant co-pathogens in polymicrobial infection of oral or periodontal origin. Metronidazole has been associated with good clinical responses in the treatment of fusobacterial and mixed
anaerobic infections [25]. Where source control is achieved, and with the aid of reliable clinical biomarkers such as C-reactive protein, antimicrobial therapy may be shortened [26, 27]. Further research into shorter course therapy for highly sensitive organisms such as *Fusobacteriaceae* could better delineate optimal antimicrobial treatment duration for patients with liver abscesses.

The strengths of this review are that it employed an extensive search strategy to identify a greater number of cases than previous reviews on the same topic. Previous literature reviews of case reports have focused mainly on only one *Fusobacteriaceae* species (*F. necrophorum* or *F. nucleatum*) [28, 29]. To our knowledge, this is the first review to include all *Fusobacteriaceae* spp., to demonstrate their homogeneity in clinical presentation, clinical findings, co-pathogens and outcomes.

Our study has several weaknesses. The main weakness is that in the case presented, *Fusobacterium nucleatum* was identified in the blood culture but not in the abscess aspirate. We remain confident in attributing *F. nucleatum* as a causative co-pathogen for a number of reasons. Firstly, delays in sample processing have been known to increase the difficulty in identifying anaerobes through conventional culture methods [30], especially in the setting of antimicrobial therapy, which was commenced in advance of abscess drainage. Studies using pyrosequencing of direct samples have shown that pyogenic abscesses are frequently polymicrobial, with the number of aetiologic agents identified significantly exceeding what is achieved using standard culture-based methods [30, 31]. Secondly, many population-based studies accept blood cultures as an appropriate standard in diagnosing causative organisms and in guiding antimicrobial treatment in pyogenic liver abscess [32]. Some cases included in our review identified *Fusobacteriaceae* by blood culture alone [33, 34]. Therefore, we have grounds to believe that *F. nucleatum* was indeed a causative agent.

In terms of other weaknesses, we reported only published observations; publications may have been biased towards those of specific interest to a journal’s readership or those that were associated with good clinical outcomes. Cases in languages other than English were excluded. Attribution of underlying source was presumptive rather than definitive in a significant number of case series. Furthermore, there was minimal information on microbiologic methods. This may have led to an over-reporting of mono-microbial infection, for example, where culture-based methods lacked sensitivity or where growth of the anaerobic flora at low quantities was under-reported.

**Conclusion**

In this case report and review of the literature, we found that fusobacterial liver abscesses resulted in good outcomes with contemporary medical and surgical care.
8. Hagelskjær Kristensen L, Prag J. Human necrobacillosis, with emphasis on Lemierre's syndrome. Clin Infect Dis. 2000;31:524–32.
9. Lemierre A. On certain septicemias due to anaerobic organisms. Lancet. 1936;2:72–7.
10. Lei W-Y, Chang W-H, Shih S-C, Liao C-J, Shih C-H. Pyogenic liver abscess with Prevotella species and Fusobacterium necrophorum as causative pathogens in an immunocompetent patient. J Formos Med Assoc. 2009;108:253–7.
11. Ergas D, Abdul-Hai A, Stoegezer Z, Menahem B-H, Miller R. Multiple pyogenic liver abscesses following hemorrhoid banding. Isr Med Assoc J. 2007;9:753–4.
12. Ma B, Forney LI, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol. 2012;66:371–89.
13. Segata N, Haafee SK, Mannion P, Lemon KP, Waldron L, Gevers D, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 2012;13:R2.
14. Swidsinski A, Dörfler Y, Loening-Baucke V, Theissig F, Rücker JC, Ismail M, et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/neurophorum. Gut. 2011;60:34–40.
15. Han YW. Fusobacterium necrophorum: a commensal-turned pathogen. Int J Med Microbiol. 2001;291:159–64.
16. Bauer C, Schoonbroodt D, Wagner C, Horsmans Y. Liver abscesses due to Fusobacterium species. Liver. 2000;20:267–8.
17. Ehlers Klug T, Rusan M, Faursted K, Ovesen T. Fusobacterium necrophorum: most prevalent pathogen in peritonillar abscesses in Denmark. Clin Infect Dis. 2009;49:1452–7.
18. Baty A, Ween MDW. Prevalence of Fusobacterium necrophorum and other upper respiratory tract pathogens isolated from throat swabs. Br J Biomed Sci. 2005;62:66–70.
19. Lo JZW, Leow JJJ, Ng PLF, Lee HQ, Mohd Noor NA, Low JK, et al. Predictors of failure of therapy in a series of 741 adult pyogenic liver abscesses. J Hepatobiliary Pancreat Sci. 2015;22:156–65.
20. Barakate MS, Stephen MS, Waugh RC, Gallagher PJ, Solomon MJ, Storey DN, et al. Pyogenic liver abscess: a review of 10 years' experience in management. Aust N Z J Surg. 1999;69:205–9.
21. Meddings L, Myers RP, Hubbard J, Shaheen AA, Laubland KD, Dixon E, et al. A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol. 2010;105:117–24.
22. Veloso ACM, van Winkelhoff AJ. Antibiotic susceptibility profiles of anaerobic pathogens in The Nethelands. Anaerobe. 2015;31:19–24.
23. Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in anaerobes isolated from clinical specimens in Kuwait hospitals: comparative analysis of 11-year data. Anaerobe. 2015;31:25–30.
24. Löffmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010;50(Suppl 15):16–23.
25. Bahmanian J, Wilson T, Diam V, Holzman RS. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis. 2004;39:1654–9.
26. Gao HN, Yuan W-X, Yang M-F, Zhao H, Hu J-H, Zhang X, et al. Clinical significance of C-reactive protein values in antibiotic treatment for pyogenic liver abscess. World J Gastroenterol. 2010;16:1174–9.
27. Veloso ACM, van Winkelhoff AJ. Antibiotic susceptibility profiles of anaerobic pathogens in The Netherlands. Anaerobe. 2015;31:19–24.
28. Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe. 2015;31:14–10.
29. Jamal W, Al Hashem G, Rotimi VO. Antimicrobial resistance among anaerobes isolated from clinical specimens in Kuwait hospitals: comparative analysis of 11-year data. Anaerobe. 2015;31:25–30.
30. Löffmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010;50(Suppl 15):16–23.
31. Bahmanian J, Wilson T, Diam V, Holzman RS. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis. 2004;39:1654–9.
32. Gao HN, Yuan W-X, Yang M-F, Zhao H, Hu J-H, Zhang X, et al. Clinical significance of C-reactive protein values in antibiotic treatment for pyogenic liver abscess. World J Gastroenterol. 2010;16:1174–9.
33. Kajiyama T, Uemura T, Kajiyama M, Karanane H, Hirato R, Uemura N, et al. Pyogenic liver abscess related to dental disease in an immunocompetent host. Int J Med Microbiol. 2008;298:675–8.
34. Nozawa Y, Joshiya S, Fukushima M, Sugiyama Y, Ichikawa Y, Kimura T, et al. A case of pyogenic liver abscess infected with Fusobacterium necrophorum depicted by microscopy and confirmed by tissue culture. Intern Med. 2008;47:1815–9.
35. Sibley CD, Church DL, Surette MG, Dowd SE, Parkins MD. Pyrosequencing reveals the complex polymicrobial nature of invasive pyogenic infections: microbial constituents of empyema, liver abscess, and intracerebral abscess. Eur J Clin Microbiol Infect Dis. 2012;31:2679–91.
36. Song YG, Shim SG, Kim KM, Lee D-H, Kim D-S, Choi S-H, et al. Profiling of the bacteria responsible for pyogenic liver abscess by 16S rRNA gene pyrosequencing. J Microbiol. 2014;52:504–9.
37. Abbas MT, Khan FY, Muthia SA, Al-Dhehwi B, Abukamar M, Etnzuki A-N. Epidemiological, Clinical Features and Outcome of Liver Abscesses: A single Reference Center Experience in Qatar. Oman Med J. 2014;29:260–3.
38. Luo M, Yang X-X, Tan B, Zhou X-P, Xia H-M, Xue J, et al. Distribution of common pathogens in patients with pyogenic liver abscesses in China: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2016;35:1557–65.
62. David H. A 21-year-old man with fever and abdominal pain after recent peritonsillar abscess drainage. Am J Emerg Med. 2009;27:515.e3–4.
63. Thatcher P. Hepatic abscesses caused by Fusobacterium necrophorum as part of the Lemierre syndrome. J Clin Gastroenterol. 2003;37:196–7.
64. Clarke MG, Kennedy NJ, Kennedy K. Serious consequences of a sore throat. Ann R Coll Surg Engl. 2003;85:242–4.
65. Athavale NV, Leitch DG, Cowling P. Liver abscesses due to Fusobacterium spp that mimic malignant metastatic liver disease. Eur J Clin Microbiol Infect Dis. 2002;21:884–6.
66. Hwang J-J, Lau Y-J, Hu B-S, Shi Z-Y, Lin Y-H. Haemophilus parainfluenzae and Fusobacterium necrophorum liver abscess: a case report. J Microbiol Immunol Infect. 2002;35:65–7.
67. Narsinghani U, Schmidt MB, Jacobs RF, Anand KS. Radiological case of the month: Lemierre syndrome. Arch Pediatr Adolesc Med. 2001;155:965–6.
68. Stallworth JR, Carroll JM. Lemierre’s syndrome: new insights into an old disease. Clin Pediatr (Phil). 1997;36:715–7.
69. Hagelskjær L, Pedersen G. Fusobacterium necrophorum septicemia complicated by liver abscess: A case report. APMIS. 1993;101:904–6.
70. Zenon GJ, Cadle RM, Hamill RJ. Ampicillin-sulbactam therapy for multiple pyogenic hepatic abscesses. Clin Pharm. 1990;9:339–47.
71. Weed TE, Merritt CR, Bowen JC. Surgical management of multiple hepatic abscesses using ultrasonography for sequential evaluation. South Med J. 1982;75:1270–3.
72. Yoneda M, Kato S, Mavatari H, Kirikoshi H, Imajo K, Fujita K, et al. Liver abscess caused by periodontal bacterial infection with Fusobacterium necrophorum. Hepatol Res. 2011;41:194–6.
73. Bytyci F, Khromenko E. Hepatic abscess caused by Fusobacterium necrophorum after a trip to the dentist. BMJ Case Rep. 2016;2016. doi:10.1136/bcr-2015-210235.
74. Goletti O, Angrisano C, Lippolis PV, Zocco G, Galatiiottio C, Lorenzetti L, et al. Percutaneous management of multiple bilateral liver abscesses complicating Crohn disease. Surg Laparosc Endosc Percutan Tech. 2001;11:131–3.
75. Posthuma EF, Bieger R, Kuyers TJ. A rare cause of a hepatic abscess: diverticulitis of the ileum. Neth J Med. 1993;42:69–72.
76. Gilbert VE. Anaerobic liver abscess: medical treatment. Ann Intern Med. 1973;78:303.